Open an account

Greenwich Lifesciences

GLSI · NASDAQ

$16.24+$1.03 (+6.77%)TodayMarket closed ·
Prev close $15.21

About GLSI

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company is headquartered in Stafford Texas, Texas and currently employs 4 full-time employees. The company went IPO on 2020-09-25. GP2 is a 9-amino acid transmembrane peptide of the human epidermal growth factor receptor 2 (HER2) /neu protein, a cell surface receptor protein that is expressed in a variety of common cancers. The company has commenced a Phase III clinical trial, Flamingo-01, an immunotherapy to prevent breast cancer recurrences. GP2 is delivered in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) to induce GP2 peptide-specific immunity. GP2 treatment is administered via an intradermal injection by mixing GP2 peptide and GM-CSF at the time of administration. Its cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells while not affecting normal cells or to deliver immune system components to inhibit the spread of cancer.

Employees
4
Headquarters
Stafford Texas, Texas
Listed
Sep 25, 2020
Sector
Health Care
Industry
Biotechnology
Website
greenwichlifesciences.com

GLSI key statistics

Market cap
238.37M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
132.50K
Volume
101.58K
Open price
$15.10
High today
$16.44
Low today
$15.10
52 Week high
$34.10
52 Week low
$7.78

Greenwich Lifesciences (GLSI) at a glance

Greenwich Lifesciences (GLSI) last traded at $16.24, with a market cap of 238.37M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $15.10 and $16.44. The current price is 7.5% above the day's low and 1.2% below its high.

Volume so far is 101.58K shares, below the average of 132.50K shares a day.

Over the past year Greenwich Lifesciences has ranged from $7.78 to $34.10, and now sits 32% of the way up that range.

Greenwich Lifesciences met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q2 FY26 it reported -$0.27 per share against an estimate of -$0.3366.

The average analyst price target is $70.38, 333.4% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 1 analyst rating say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 3 analystsAvg $70.38
Low
$69.69
Now
$16.24
High
$72.45

GLSI earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 8.9% on average.

  1. Q3 FY24: reported -$0.20 per share against an estimate of -$0.2142
  2. Q4 FY24: reported -$0.61 per share against an estimate of -$0.2142
  3. Q1 FY25: reported -$0.25 per share against an estimate of -$0.2448
  4. Q2 FY25: reported -$0.30 per share against an estimate of -$0.2448
  5. Q3 FY25: reported -$0.30 per share against an estimate of -$0.3009
  6. Q4 FY25: reported -$0.58 per share against an estimate of -$0.3264
  7. Q1 FY26: reported -$0.39 per share against an estimate of -$0.3366
  8. Q2 FY26: reported -$0.27 per share against an estimate of -$0.3366

GLSI news

  • Avi Kapoor

    Why Kyverna Therapeutics Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket

  • Press releasePRNewswire

    $170B Patent Cliff Ignites Biotech Deal Wave: Late-Stage Platforms Command Premium

  • Avi Kapoor

    Sarepta Therapeutics, Lands' End, USA Rare Earth, CoreWeave And Other Big Stocks Moving Higher On Monday

  • Market-Moving News for January 22nd

  • Press releasePRNewswire

    How $594B in Precision Tech is Cracking the Metastatic Cancer Code

  • Vandana Singh

    What's Going On With Greenwich LifeSciences Friday?

  • 12 Health Care Stocks Moving In Thursday's Pre-Market Session

  • Press releasePRNewswire

    SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Greenwich LifeSciences, Inc. (NASDAQ: GLSI)

Similar companies

Companies in the same industry as Greenwich Lifesciences

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.